Track topics on Twitter Track topics that are important to you
VANCOUVER, British Columbia, Oct. 28, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF), a growth oriented and diversified international cannabis company, is pleased to provide comment regarding Statistics Canada’s August 2019 cannabis retail sales data (the “Sales Data”). The Sales Data reflects monthly retail sales for the Canadian adult-use market in each respective province.
Canadian adult-use cannabis stores reported record sales of C$127.4 million in August, achieving month over month (“MoM”) growth on both an aggregate sales and a sales per day basis of 19 per-cent. When extrapolated, August’s record sales numbers equate to a 2019 annual run-run of approximately C$1.5 billion.
Across Canada, licensed brick-and-mortar retail store locations experienced MoM growth of 14 per-cent in August and 18 per-cent in September respectively. As of October 28, 2019, it is estimated that there are 647 licensed and authorized cannabis retail stores across Canada.
With a robust portfolio of upstream and downstream cannabis assets, AgraFlora is well equipped to service Canada’s maturing cannabis flower marketplace, as well as the Country’s formalized cannabis 2.0 landscape; including the production and sale of edible cannabis, cannabis extracts and cannabis topicals.
To date, the Company has deployed over C$115 million in associated plant, property and equipment (“PPE”) expenditures related to its cultivation, manufacturing and distribution assets. These accretive PPE expenditures have positioned AgraFlora to capture defendable market share within Canada’s growing domestic cannabis arena.
A summary of related expenditures to date associated with the company's upstream and downstream cannabis asset portfolio include:
Brandon Boddy, Chairman and Chief Executive Officer of AgraFlora stated: “The state of the Canadian domestic cannabis marketplace remains strong, with robust month over month sales figures and a growing authorized brick and mortar footprint. Due to astute engineering accomplishments, corporate planning and operational execution we have aggregated a diverse portfolio of upstream and downstream cannabis assets and associated infrastructure, which will act as a supply cornerstone into the next decade.
We remain optimistic that Health Canada’s anticipated cannabidiol regulations will classify CBD as a natural health product, enabling widespread proliferation across Canada and unlocking hidden value within AgraFlora’s cannabis value chain. As CBD continues its ubiquitous permutation of CPGs, AgraFlora remains well equipped to capitalize on a shifting regulatory environment, while capturing material market share of Canada’s adult-use arena.”
DELTA GREENHOUSE FACILITY
AgraFlora’s Delta Greenhouse Facility is a state-of-the-art pressurized, semi-open Venlo greenhouse, which is widely considered to be one of the most technically advanced and environmentally friendly greenhouse operations in the world. The Company’s Delta Greenhouse Facility boasts the following industry-leading cultivation infrastructure:
AgraFlora’s Phase 1 retrofit of its flagship Delta greenhouse complex comprises approximately 431,000 square feet of cultivation/processing expanse, including over 130,000 square feet of net flower canopy and is estimated to produce 15 million grams of premium cannabis annually. With the completion of the Phase 1 retrofit, the Company's current annual projected output of dried flower is approximately 160,000 kilograms including 2020 forecasted production at its purpose built AAA Heidelberg craft cannabis cultivation facility. In addition, AgraFlora anticipates the successful recapture of over one million grams of premium cannabis trim to be manufactured into ancillary value-added cannabis products on an annualized basis.
Additionally, the Delta Greenhouse Complex is equipped with a full-spectrum industrial hemp licence (“IHL”) that permits following associated cultivation, propagation, nursery and product formulation/manufacturing capabilities:
AgraFlora anticipates that once fully optimized, its planned industrial hemp operations will provide ample feedstock inputs for the company's unique portfolio of cannabinoid product formulation and downstream assets, affording the company the ability to capture material cash flows throughout each link of the cannabis value chain.
All planned hemp cultivation at the Company's Delta Greenhouse Facility will utilize existing greenhouse infrastructure that is not currently earmarked for propagation and/or cannabis business initiatives. As a result, AgraFlora's proposed hemp cultivation activities will not impact current propagation and eventual cannabis cultivation operations. Hemp cultivation will not interfere with the planned cannabis cultivation activities at the Delta Greenhouse Facility, nor will it reduce the cannabis cultivation design capacity of the Company's Delta Greenhouse Facility.
WINNIPEG EDIBLES FACILITY
AgraFlora is in the process of constructing a 51,500 square foot GMP edibles manufacturing facility in Winnipeg, Manitoba (the “Winnipeg Edibles Facility”), which boasts 33,000 square feet of production area, as well as an 8,000 square foot pharmaceutical-grade research and development (“R&D”) laboratory.
The Winnipeg Edibles Facility will be fully operational by the first quarter of 2020 and, once optimized, is forecasted to be capable of generating in excess of $750 million in annual sales revenue. Projected revenues are derived from logical assumptions including the facility achieving full capacity and the equipment operating seven days per week, 20 hours per day with all product being sold to downstream distributors, with the sales price based on current comparable retail pricing in the United States.
The Winnipeg Edibles Facility will be operated by a roster of experienced chocolatiers and confectioners, as well as equipped with state-of-the-art manufacturing equipment capable of producing an assortment of both cannabinoid/terpene-infused products for medicinal, functional and adult use, including:
The Company anticipates the facility will be fully operational by the first quarter of 2020. Existing downstream capabilities will be buoyed by one of Canada's leading sales forces, affording AgraFlora the ability to secure immediate shelf space across all major retail channels.
About AgraFlora Organics International Inc.
AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Services Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company is also retrofitting a 51,500-square-foot good manufacturing practice (“GMP”) edibles manufacturing facility in Winnipeg, Manitoba. AgraFlora has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.
ON BEHALF OF THE BOARD OF DIRECTORS
Chairman & CEO
T: (604) 398-3147
|For additional information:|
|AgraFlora Organics International Inc.|
T: (800) 783-6056
|For French inquiries:|
Remy Scalabrini, Maricom Inc.
T: (888) 585-MARI
The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...